Abstract PO4-05-02: The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer

• DOI: 10.1158/1538-7445.sabcs23-po4-05-02
• Publication Date: 2024-05-02T07:15:12Z
• Authors: Wakako Tajiri; Yoshiaki Nakamura; Junji Kawasaki; Yumiko Koi; Sayuri Akiyoshi; Chinami Koga; Eriko Tokunaga
• Keywords: 0301 basic medicine; 03 medical and health sciences

Abstract Background A non-luminal disease score (NOLUS) is pathology-based predictive model to identify PAM50 within HR+/HER2-negative breast cancer. NOLUS a new model, therefore, its clinical utility not sufficiently elucidated. In this study, the impact of was investigated in unresectable/metastatic estrogen receptor (ER) positive (ER+)/HER2-negative Patients and Methods The total 61 patients, who were diagnosed ER+/HER2-negative cancer between 2010 Apr 2023, included study. status calculated with formula:−0.45∗ER −0.28∗PR +0.27∗Ki67 + 73.02 as NOLUS-positive (≥51.38) NOLUS-negative (< 51.38) according previous reports (Pascual T et al, Front Oncol 2019; 9:303). relationships clinicopathological factors prognosis analyzed. Results Among 10 patients (16.4%) 51 (83.6%) NOLOS-negative. NOLUS-positivity significantly associated progesterone (PgR)-negativity (p=0.0051) higher histological grade (0.0234), had tendency have shorter recurrence free interval liver metastasis. age, menopausal Ki67. proportion whose first line treatment for endocrine therapy or without targeted group. overall survival (OS; log-rank p=0.0012). Uni- multivariate analysis, poor prognostic factor OS. Conclusion poor. useful predict these patients. Table. characteristics. Univariate analysis OS after Citation Format: Wakako Tajiri, Yoshiaki Nakamura, Junji Kawasaki, Yumiko Koi, Sayuri Akiyoshi, Chinami Koga, Eriko Tokunaga. hormone receptor-positive (HR+)/HER2-negative [abstract]. In: Proceedings 2023 San Antonio Breast Cancer Symposium; Dec 5-9; Antonio, TX. Philadelphia (PA): AACR; Res 2024;84(9 Suppl):Abstract nr PO4-05-02.